Cannabis Helps IBS Patients Spend Less Time in Hospital

cannabis IBS patients, marijuana irritable bowl syndrome
Photo by MarketeeringGroup

The results of a current study demonstrate that patients with irritable bowel syndrome (IBS) who have a background of cannabis utilize spent significantly less time at the hospital also had reduced inpatient healthcare usage and related costs. A report about the study,”Association between cannabis use and health care usage in patients with irritable bowel syndrome: A retrospective cohort analysis,” was published a month in the journal Cereus.

Hospital of Cook County in Chicago examined hospitalization data from over 9,000 patients within a four-year period who had a primary discharge diagnosis of IBS. Cannabis consumers and non-users were compared for various clinical results.

The researchers found that the 246 patients that had a background of using cannabis had a shorter average stay in the hospital (2.8 times versus 3.6 times for non-users) and so are not as likely to have had specific medical procedures connected with IBS diagnoses and therapy.

“Our analysis is the first nationwide cohort study to assess the association between cannabis use and health care usage in patients with IBS,” they wrote. “We have discovered that cannabis use is associated with a decrease usage of endoscopic procedures, lower amount of stay, and reduced median overall cost of hospitalization.”

Cannabis Users Additionally Had diminished Hospitalization Prices
The reduced length of the normal hospital stay and the diminished use of health processes translated into ordinary total charges for its hospitalizations to be greater than $3,000 less for cannabis users compared to patients who didn’t report using cannabis.

“Our analysis offers evidence to indicate that cannabis use may reduce health care utilization and costs among hospitalized patients with IBS,” the investigators concluded. “These findings are probably attributable to the consequences of cannabis’ active chemical, THC, on gastrointestinal motility and colonic compliance”

The researchers noted a number of limitations of this analysis, including a scarcity of information for the severity of disease for those patients and the therapeutic regimens used while they were at the hospital. The analysis also noted that advice on the dosing and procedure for ingestion of cannabis wasn’t available and recommended further study on the impact of cannabis on IBS and also the potential for therapeutic usage.

“The use of cannabis in the treatment of IBS has potential for considerable impact in the individual and population level awarded the burden of IBS on individual wellbeing and health care expenses,” they wrote.